| P2093 | author name string | Jian Ding | |
| | Yi-Xue Li | |
| | Ling-Hua Meng | |
| | Chen-Liang Guo | |
| | Jia-Jie Shi | |
| | Si-Meng Chen | |
| P2860 | cites work | Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR. | Q39401629 |
| | WJD008, a dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin inhibitor, prevents PI3K signaling and inhibits the proliferation of transformed cells with oncogenic PI3K mutant | Q39696876 |
| | Mammalian Hsp22 is a heat-inducible small heat-shock protein with chaperone-like activity | Q42214286 |
| | AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity | Q43211411 |
| | Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study | Q43503861 |
| | HspB8 participates in protein quality control by a non-chaperone-like mechanism that requires eIF2{alpha} phosphorylation | Q45292128 |
| | Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome | Q46782051 |
| | Combination treatment of RAD001 and BEZ235 exhibits synergistic antitumor activity via down-regulation of p-4E-BP1/Mcl-1 in small cell lung cancer. | Q47184289 |
| | Heat shock protein 22 overexpression is associated with the progression and prognosis in gastric cancer. | Q54354560 |
| | Phosphorylation of human small heat shock protein HspB8 (Hsp22) by ERK1 protein kinase. | Q54593816 |
| | Toward rapamycin analog (rapalog)-based precision cancer therapy | Q26795606 |
| | Ras, PI(3)K and mTOR signalling controls tumour cell growth | Q29614734 |
| | Molecular mechanisms of mTOR-mediated translational control | Q29615529 |
| | CellMiner: a relational database and query tool for the NCI-60 cancer cell lines | Q33472990 |
| | Mechanisms of tamoxifen resistance | Q34378877 |
| | High-throughput ectopic expression screen for tamoxifen resistance identifies an atypical kinase that blocks autophagy. | Q34549892 |
| | Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions. | Q34657786 |
| | Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma | Q36287995 |
| | Endocrine resistance in breast cancer--An overview and update | Q36386322 |
| | Mechanisms of Endocrine Resistance in Breast Cancer | Q36851417 |
| | Tamoxifen resistance in breast cancer | Q37224555 |
| | Understanding breast cancer - The long and winding road | Q37634220 |
| | Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro | Q37690245 |
| | Inhibiting 4EBP1 in glioblastoma. | Q38659417 |
| | Cancer Statistics, 2017. | Q39038674 |
| | LMTK3 is implicated in endocrine resistance via multiple signaling pathways. | Q39301431 |
| P433 | issue | 8 | |
| P921 | main subject | tamoxifen | Q412178 |
| P304 | page(s) | 1338-1346 | |
| P577 | publication date | 2018-01-18 | |
| P1433 | published in | Acta Pharmacologica Sinica | Q15749885 |
| P1476 | title | The mTOR inhibitor AZD8055 overcomes tamoxifen resistance in breast cancer cells by down-regulating HSPB8 | |
| P478 | volume | 39 | |